• Dr. Mutyam received his PhD in Biology from the University of Dayton in 2012. In 2013, he joined UAB's Division of Pulmonary, Allergy, and Critical Care Medicine as a postdoctoral research fellow. In the laboratory of Dr. Steven Rowe, Dr. Mutyam investigated the role of premature stop codons in CFTR gene, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases. Following his research fellow position, the division hired him as an instructor faculty in 2016. Dr. Mutyam is an active member in the American Physiological Society, a Member at Large in the Birmingham Physiology Network, an associate editor for Frontiers in Pharmacology, and an Editorial Board Member for the Journal of Pediatric Care Insight. His ongoing laboratory research is focused on understanding the basic mechanistic defects underlying ion transport in CF airway epithelial cells and its associated physiology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Novel correctors and potentiators enhance translational readthrough in CFTR nonsense mutationsAmerican Journal of Respiratory Cell and Molecular Biology.  64:604-616. 2021
    2021 Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutationJournal of Cystic Fibrosis2021
    2020 Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutationsPediatric Pulmonology.  55:1838-1842. 2020
    2017 Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequencesHuman Molecular Genetics.  26:3116-3129. 2017
    2017 Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutationJournal of Cystic Fibrosis.  16:24-29. 2017
    2016 Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression 2016
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2014 Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftorAmerican Journal of Respiratory Cell and Molecular Biology.  50:805-816. 2014
    2011 Dynamic regulation of aquaglyceroporin expression in erythrocyte cultures from cold- and warm-acclimated cope's gray treefrog, Hyla chrysoscelisJournal of Experimental Zoology Part A: Ecological Genetics and Physiology.  315 A:424-437. 2011
    2011 Endo-porter-mediated delivery of phosphorodiamidate morpholino oligos (PMOs) in erythrocyte suspension cultures from cope's gray treefrog hyla chrysoscelis 2011
    2009 Altered regulation of aquaporin gene expression in allergen and IL-13-induced mouse models of asthmaCytokine.  46:111-118. 2009

    Research Overview

  • Dr. Mutyam's current research focuses on identifying and testing the efficacy of novel drugs using In vitro cell culture model systems for potential treatment of genetic diseases caused by nonsense mutations. He has successfully advanced the use of high throughput screening technology to identify novel CF drugs and his initial drug screening efforts have lead to the discovery of several lead agents that has been shown restore CFTR function. Dr. Mutyam is also leading efforts to establish primary airway epithelial cells from individual Cystic Fibrosis patients with unique genetic defects as readily available laboratory models for drug screening using state-of-the-art tissue culture techniques.
  • Education And Training

  • Doctor of Philosophy in Biology, University of Dayton 2012
  • Full Name

  • Venkateshwar Mutyam